HTG Molecular Diagnostics, Inc.
HTGMQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $6 | $9 | $9 | $19 |
| % Growth | -28.5% | 4.2% | -55.5% | – |
| Cost of Goods Sold | $5 | $4 | $4 | $9 |
| Gross Profit | $2 | $5 | $5 | $10 |
| % Margin | 28.2% | 54% | 53.3% | 53.6% |
| R&D Expenses | $7 | $6 | $6 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $16 | $17 | $18 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23 | $23 | $25 | $29 |
| Operating Income | -$21 | -$18 | -$20 | -$19 |
| % Margin | -327.2% | -200.1% | -229.1% | -98.7% |
| Other Income/Exp. Net | -$1 | $1 | -$1 | -$0 |
| Pre-Tax Income | -$22 | -$17 | -$21 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$17 | -$21 | -$19 |
| % Margin | -339.2% | -192.5% | -244.1% | -100.5% |
| EPS | -24.28 | -29.66 | -54.12 | -91.17 |
| % Growth | 18.1% | 45.2% | 40.6% | – |
| EPS Diluted | -24.28 | -29.66 | -54.12 | -91.17 |
| Weighted Avg Shares Out | 1 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$20 | -$15 | -$18 | -$17 |
| % Margin | -316.4% | -172.4% | -216.2% | -88.9% |